In adults with T1D and overweight or obesity, adding GLP-1 RAs to insulin reduces weight, HbA 1c levels, and insulin dose

Key Points

• To evaluate the effects of adding GLP-1 receptor agonists (RAs) to insulin therapy in adults with Type 1 Diabetes (T1D) who are overweight or obese.
• Conducted an observational trial with adults diagnosed with T1D and overweight or obesity.
• Administered GLP-1 RAs in addition to standard insulin therapy.
• Measured changes in weight, HbA1c levels, and insulin dosage during the trial.
• Participants experienced a significant reduction in weight after adding GLP-1 RAs.
• HbA1c levels decreased notably, indicating improved blood sugar control.
• The required doses of insulin were reduced among participants.